<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111538</url>
  </required_header>
  <id_info>
    <org_study_id>20130026923</org_study_id>
    <nct_id>NCT02111538</nct_id>
  </id_info>
  <brief_title>Body Composition in Systemic Amyloidosis</brief_title>
  <acronym>BIVAmyloid</acronym>
  <official_title>Prognostic Value of Phase Angle in Systemic Immunoglobulin Light-chain (AL) Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akern Srl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malnutrition is a prominent clinical feature of patients affected by systemic immunoglobulin
      light-chain amyloidosis (AL), with a prevalence ranging between 25-50%. Although the
      prognosis predominantly depend on the presence and severity of cardiac involvement, it was
      shown that malnutrition is an independent predictor of survival and quality of life. However,
      the assessment of nutritional status by common indices based on anthropometry is not always
      feasible and accurate due to reduced performance status and/or the presence of fluid
      imbalances (for example edema and ascites). Several recent studies have demonstrated the
      prognostic value of the phase angle. Moreover, the value is supported by its applicability to
      patients who are bedridden or present alterations in the state of hydration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause mortality at 12 months since baseline assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Association between phase angle and quality of life at baseline and 6 months. Association between changes in phase angle and in quality of life at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Association between phase angle and its changes at 6 months and mortality at 12 months.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Amyloidosis</arm_group_label>
    <description>Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary advice</intervention_name>
    <description>Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for</description>
    <arm_group_label>Amyloidosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis
        attending the Amyloidosis Research and Treatment Center (Fondazione IRCCS Policlinico San
        Matteo)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of systemic immunoglobulin light-chain (AL) amyloidosis

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Ongoing artificial nutrition

          -  Unavailability to planned measurements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riccardo Caccialanza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giampaolo Merlini, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riccardo Caccialanza, MD</last_name>
    <phone>00390382501615</phone>
    <email>r.caccialanza@smatteo.pv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Caccialanza, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emanuele Cereda, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Palladini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giampaolo Merlini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiara Bonardi, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, Lavatelli F, Marena C, Merlini G. Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment. JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):891-4. doi: 10.1177/0148607113501328. Epub 2013 Sep 26.</citation>
    <PMID>24072737</PMID>
  </reference>
  <reference>
    <citation>Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, Lavatelli F, Merlini G. Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Ann Hematol. 2012 Mar;91(3):399-406. doi: 10.1007/s00277-011-1309-x. Epub 2011 Aug 9.</citation>
    <PMID>21826471</PMID>
  </reference>
  <reference>
    <citation>Caccialanza R, Palladini G, Klersy C, Cena H, Vagia C, Cameletti B, Russo P, Lavatelli F, Merlini G. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr. 2006 Feb;83(2):350-4.</citation>
    <PMID>16469994</PMID>
  </reference>
  <reference>
    <citation>Sattianayagam PT, Lane T, Fox Z, Petrie A, Gibbs SD, Pinney JH, Risom SS, Rowczenio DM, Wechalekar AD, Lachmann HJ, Gilbertson JA, Hawkins PN, Gillmore JD. A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica. 2013 Jan;98(1):136-40. doi: 10.3324/haematol.2012.070359. Epub 2012 Sep 14.</citation>
    <PMID>22983575</PMID>
  </reference>
  <reference>
    <citation>Norman K, Stob√§us N, Pirlich M, Bosy-Westphal A. Bioelectrical phase angle and impedance vector analysis--clinical relevance and applicability of impedance parameters. Clin Nutr. 2012 Dec;31(6):854-61. doi: 10.1016/j.clnu.2012.05.008. Epub 2012 Jun 12. Review.</citation>
    <PMID>22698802</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Riccardo Caccialanza</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulin Light Chains</mesh_term>
    <mesh_term>Bence Jones Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

